LHC Group Receives a Rating Update from a Top Analyst

By Austin Angelo

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on LHC Group (NASDAQ: LHCG) today and set a price target of $85. The company’s shares closed yesterday at $63.90.

Wiederhorn commented:

“We attended meetings with the LHC Group management and believe the company is well positioned for growth given $180M of recently acquired revenues and the accretion from the pending Almost Family transaction. Although the outlook for reimbursement will always be a risk, the outlook for the business has greatly improved following the HHGM delay, but we continue to keep an eye on the potential impact of the fluid noise out of Washington around Medicare reimbursement and the rural add-on.”

According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 14.6% and a 68.9% success rate. Wiederhorn covers the Services sector, focusing on stocks such as Cross Country Healthcare, Addus Homecare Corp, and Envision Healthcare.

LHC Group has an analyst consensus of Strong Buy, with a price target consensus of $80.17.

Based on LHC Group’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $273 million and quarterly net profit of $10.91 million. In comparison, last year the company earned revenue of $231 million and had a net profit of $9.62 million.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

LHC Group, Inc. provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Community-Based Services and Facility-Based Services.